“We are very pleased to have attracted these outstanding oncologists to our Clinical Advisory Board,” stated Roger Sharpe, President of Nometics Inc. “They bring great depth of experience and knowledge in all areas of clinical oncology & drug development to our company.”
About Nometics Inc.
Nometics Inc. is a private specialty pharmaceutical company focused on the development & commercialization of late stage oncology products. The company’s lead compound, NOVade™ is a low-dose formulation of transdermal nitroglycerin. NOVade™ has demonstrated pre-clinical and clinical success in treating a wide variety of cancers including non-small cell lung, breast, melanoma and prostate cancer (the latter was the subject of a phase I/II trial). NOVade™ has demonstrated the capacity to work both alone, or in combination with standard anti-neoplastic therapies.
Nometics Inc. is building on clinical results and a strong research base which has elucidated a unique mode of action in metastatic cancer cells. The Company expects to start advanced clinical trials in 2009. (www.nometicsinc.com)